USX: Introducing PharmaZen Limited

Pharmazen Limited Issuer Profile

PharmaZen Ltd (PAZ), trading as Waitaki Biosciences, is a a biotechnological company based in Christchurch, New Zealand.

It is principally involved in the development, manufacture and business to business marketing of specialised nutritional ingredients for human and companion animal dietary supplement products. Exported product typically generates in excess of 90% of revenune annually. 

PharmaZen offers its international customer base a portfolio of branded ingredients with specific functionality in bone and joint health, anti-inflammation, immune support, digestive health and anti-oxidant capability. 

The company is chaired by Maxwell Shepherd, with Kenneth Fergus, Wayne Burt and Peter Dobbs in directorship roles.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

PYS - PaySauce to announce F26 full year results on 27 May 2026
PEB - Draft LCD Proposes Medicare Coverage for Triage and Triage
MEL - Meridian Energy monthly operating report for April 2026
FBU - Sale of South Australian property
AIR - Air New Zealand market update
May 14th Morning Report
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million